SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Video

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Related Videos
Related Content
Comparative Effectiveness of Remdesivir in Early COVID-19 Treatment

Comparative Effectiveness of Remdesivir in Early COVID-19 Treatment

April 23rd 2024
Article
Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

November 6th 2023
Podcast
Addressing Public Health Concerns Over Avian Flu

Addressing Public Health Concerns Over Avian Flu

April 21st 2024
Article
Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022
Podcast
Veterans With COVID-19 Run Greater Risk of Preventable Hospitalization

Veterans With COVID-19 Run Greater Risk of Preventable Hospitalization

April 17th 2024
Article
Antibiotics for Most Lower Tract Respiratory Infections Are Not Efficacious

Antibiotics for Most Lower Tract Respiratory Infections Are Not Efficacious

April 17th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.